Krystal Biotech, Inc. (KRYS) Stock Price & Analysis
Krystal Biotech, Inc. (KRYS) fell 3.56% to USD 358.24 as of September 8, 2026 at 05:02 UTC, according to Nexqual real-time market data.
KRYS last closed at USD 358.24; the session ranged USD 353.75–371.99 on volume of 323,022 shares. Market capitalization is —, with a 52-week range of USD 136.73–382.54 (NMS). Source: Nexqual, September 8, 2026 at 05:02 UTC.
Key Statistics (as of September 8, 2026 at 05:02 UTC)
| Price | USD 358.24 |
|---|---|
| Change | ▼ 3.56% (down) |
| Previous Close | USD 358.24 |
| Open | USD 358.24 |
| Day Range | USD 353.75 – 371.99 |
| 52-Week Range | USD 136.73 – 382.54 |
| Volume | 323,022 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (KRYS)
Nexqual's technical model rates KRYS "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 05:02 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.87 (neutral) |
| vs SMA50 | Above (USD 349.76) |
| MACD | 6.87 (positive) |
From Krystal Biotech, Inc.'s Latest SEC 10-K Filing (filed 2026-02-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Redosable Gene Therapy Platform We believe that certain inherent features of the HSV-1 virus, combined with the modifications we have made to the viral backbone provides our proprietary gene therapy platform with specific advantages over other viral and non-viral vector platforms and represents an opportunity to generate a portfolio of highly differentiated and potentially first-in-class or best-in-class genetic medicines.
- Since our first commercial launch of VYJUVEK in the United States, we have reported $730.3 million in net product revenue. 6 Regulatory Status On May 19, 2023, the FDA approved VYJUVEK, the first ever redosable gene therapy, for treating patients, six months of age or older, suffering from DEB.
- KB408 KB408 is an inhaled (nebulized) formulation of our proprietary vector, designed to deliver two copies of the SERPINA1 transgene that encodes functional, full-length human AAT protein, for the treatment of AATD.
- In support of the Phase 2 study, we developed and validated a décolleté-specific photonumeric scale ("JDWS") which was submitted to the FDA in the second half of 2025.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 102.74 | ▼ 2.54% |
| ARGX | argenx SE | USD 1,033.15 | ▼ 2.11% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 84.95 | ▲ 0% |
| KNSA | Kiniksa Pharmaceuticals Interna | USD 77.91 | ▼ 2.48% |
| PTGX | Protagonist Therapeutics, Inc. | USD 145.72 | ▼ 0.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:02 UTC. This page is informational and not investment advice.